PODCAST: A Bubble Tea IPO Freeze, and a Revenue-less Drug Maker
China's securities regulator puts the brakes on new bubble tea IPOs in Hong Kong. Is this China's latest step to assert its authority over the former British colony? And former drug making highflyer Ascletis has become revenue-less after its earlier drugs fizzled. Now the company is hoping to revive its fortunes with a new weight-loss drug from the same class as Ozempic.
Facing revenue crisis, Ascletis Pharma tries to bulk up with obesity drugs
The drug maker failed to generate any revenue in the first half of 2024 even with three major commercialized products in hand Key Takeaways: Ascletis Pharma has shifted to weight…
FAST NEWS: Ascletis Pharma’s loss narrows as core product sales surge
The latest: Ascletis Pharma Inc. (1672.HK) announced Tuesday its net loss narrowed sharply in the first half of this year to 16.56 million yuan ($2.3 million) from an 88 million…
FAST NEWS: Ascletis Pharma’s Monkeypox Drug Gets IND Approval
The latest: Ascletis Pharma Inc. (1672.HK) announced on Thursday that the China National Medical Products Administration (NMPA) has approved an Investigational New Drug (IND) application for its oral viral polymerase…
FAST NEWS: Ascletis Covid, Monkeypox Virus Inhibitor Gets U.S. Patent
The latest: Ascletis Pharma Inc. (1672.HK) said on Monday the U.S. Patent and Trademark Office (USPTO) has granted it a patent for its oral viral polymerase inhibitor ASC10 and its…
Could Covid Drugs Help Cure Financial Ills at Ascletis Pharma?
Ascletis Pharma has applied for U.S. FDA approval to start clinical trials on a new Covid drug, ASC10 Key Takeaways: Ascletis Pharma is ready to put its new Covid drug…
FAST NEWS: Ascletis Pharma Files to Sell Ritonavir in Four European Countries
The latest: Ascletis Pharma Inc. (1672.HK) announced on Sunday that it has submitted marketing authorization applications for its oral ritonavir 100 mg film-coated tablets in Germany, France, Ireland and the…
